EUVIMEDEUVIMED entdecken
VergleichsstudieKlinische StudieOpen Access · CC BY 4.0

[18F]Fluciclovine PET/CT versus [18F]DCFPyL PET/CT in patients with biochemical recurrence of prostate cancer after robot-assisted radical prostatectomy: a prospective, single-center, single-arm, comparative imaging trial

Wietske I Luining iD, André N Vis, Maarten L Donswijk, Jose C C Koppes, Pim J van Leeuwen, Frederik Oudshoorn, Matthijs C F Cysouw, Daniela E Oprea-Lager

European Journal of Nuclear Medicine and Molecular Imaging · 2026

DOI: 10.1007/s00259-026-07816-3 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2026. Verfasst von Wietske I Luining und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Amsterdam University Medical Center, VU university, location VUmc, De Boelelaan 1117, 1081 HV , Amsterdam, The Netherlands. w.…. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Cyclobutanes, Positron Emission Tomography Computed Tomography, Carboxylic Acids. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Curium Pharma B.V..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: The current EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines recommend radiolabeled prostate-specific membrane antigen (PSMA), choline, or fluciclovine PET/CT at biochemical recurrence (BCR) of prostate cancer (PCa) after radical prostatectomy. While studies compared [68Ga]Ga-PSMA-11 and [18F]Fluciclovine, data on 18F-labelled PSMA-ligands versus [18F]Fluciclovine in patients with low prostate-specific antigen (PSA) levels (< 2 ng/mL) are limited. This study compared the detection rates of [18F]Fluciclovine and [18F]DCFPyL PET/CT in patients with BCR after robot-assisted radical prostatectomy (RARP). Secondary objectives included stratifying detection rates by PSA level, anatomical regions and assessing inter-observer agreement. METHODS: In this prospective, single-center study, patients with BCR (PSA 0.2-2.0 ng/mL) underwent both [18F]Fluciclovine and [18F]DCFPyL PET/CT within 15 days. Three blinded nuclear medicine experts independently reviewed all scans. Lesions were classified as positive or negative in predefined regions (i.e., prostate bed, pelvic and extra-pelvic lymph nodes, bone, and visceral). Discrepancies were resolved by consensus, defined as majority agreement (≥ 2/3 readers). Inter-observer agreement was assessed using Fleiss’ kappa. RESULTS: Overall scan positivity was 44% (22/50 patients) for [18F]DCFPyL PET/CT and 24% (12/50) for [18F]Fluciclovine PET/CT (p = 0.018). Detection rates increased with rising PSA levels for both tracers. Local recurrence was detected by both tracers in 16% (8/50) of patients. Metastatic disease detection rates for [18F]DCFPyL versus [18F]Fluciclovine were 22% vs. 8.0% for pelvic lymph nodes (p = 0.016), and 6.0% versus 2.0% for distant metastases (p = 0.50), respectively. Inter-observer agreement was moderate for both tracers (κ = 0.59 for [18F]DCFPyL and κ = 0.55 for [18F]Fluciclovine). CONCLUSION: This study demonstrated the superiority of [18F]DCFPyL over [18F]Fluciclovine in detecting pelvic lymph node metastases in patients presenting with BCR after RARP at low PSA levels. These findings suggest the potential of [18F]DCFPyL PET/CT to facilitate earlier and more personalized salvage treatment strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsCyclobutanesPositron Emission Tomography Computed TomographyCarboxylic AcidsLysineProstatectomyUreaRobotic Surgical ProceduresHumansMaleProspective StudiesAgedMiddle AgedRecurrenceGlutaratesPyridines

Stichwörter der Autor:innen

Biochemical recurrenceFACBCPET/CTProstate cancer[18F]DCFPyL[18F]Fluciclovine

Substanzen

CyclobutanesCarboxylic Acidsfluciclovine F-18LysinepiflufolastatUreaGlutaratesPyridines

Autor:innen und Institutionen

  • Department of Urology, Amsterdam University Medical Center, VU university, location VUmc, De Boelelaan 1117, 1081 HV , Amsterdam, The Netherlands. w.i.luining@amsterdamumc.nl.
  • Department of Radiology & Nuclear Medicine, Amsterdam University Medical Center, Amsterdam, The Netherlands. w.i.luining@amsterdamumc.nl.
  • Prostate Cancer Network the Netherlands, Amsterdam, The Netherlands. w.i.luining@amsterdamumc.nl.
  • Cancer Center Amsterdam, Amsterdam University Medical Center, Amsterdam, The Netherlands. w.i.luining@amsterdamumc.nl.
  • Department of Urology, Amsterdam University Medical Center, VU university, location VUmc, De Boelelaan 1117, 1081 HV , Amsterdam, The Netherlands.
  • Prostate Cancer Network the Netherlands, Amsterdam, The Netherlands.

ORCID-Profile: Wietske I Luining

Förderung

  • Curium Pharma B.V.

Zitieren

APA

Luining, W. I., Vis, A. N., Donswijk, M. L., Koppes, J. C. C., van Leeuwen, P. J., Oudshoorn, F., Cysouw, M. C. F., & Oprea-Lager, D. E. (2026). [18F]Fluciclovine PET/CT versus [18F]DCFPyL PET/CT in patients with biochemical recurrence of prostate cancer after robot-assisted radical prostatectomy: a prospective, single-center, single-arm, comparative imaging trial. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-026-07816-3

Vancouver

Luining WI, Vis AN, Donswijk ML, Koppes JCC, van Leeuwen PJ, Oudshoorn F, et al. [18F]Fluciclovine PET/CT versus [18F]DCFPyL PET/CT in patients with biochemical recurrence of prostate cancer after robot-assisted radical prostatectomy: a prospective, single-center, single-arm, comparative imaging trial. European Journal of Nuclear Medicine and Molecular Imaging. 2026. doi:10.1007/s00259-026-07816-3

BibTeX
@article{Luining2026,
  author = {Luining, Wietske I and Vis, André N and Donswijk, Maarten L and Koppes, Jose C C and van Leeuwen, Pim J and Oudshoorn, Frederik and Cysouw, Matthijs C F and Oprea-Lager, Daniela E},
  title = {[18F]Fluciclovine PET/CT versus [18F]DCFPyL PET/CT in patients with biochemical recurrence of prostate cancer after robot-assisted radical prostatectomy: a prospective, single-center, single-arm, comparative imaging trial},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2026},
  doi = {10.1007/s00259-026-07816-3}
}
Kostenlos starten →